chrisvoncsefalvay/vaers-outcomes huggingface dataset:
allergic reaction; lightheadedness; Breathing difficult; Lymph nodes, enlarged; Swollen lymph nodes; Painful lymphadenopathy; itchy; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (allergic reaction), DIZZINESS (lightheadedness), DYSPNOEA (Breathing difficult), LYMPHADENOPATHY (Lymph nodes, enlarged ) and LYMPHADENOPATHY (Swollen lymph nodes) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Hypertension, Diabetes and Diabetic neuropathy.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Mar-2021, the patient experienced HYPERSENSITIVITY (allergic reaction), DIZZINESS (lightheadedness), DYSPNOEA (Breathing difficult), LYMPHADENOPATHY (Lymph nodes, enlarged ), LYMPHADENOPATHY (Swollen lymph nodes), LYMPHADENOPATHY (Painful lymphadenopathy) and PRURITUS (itchy). At the time of the report, HYPERSENSITIVITY (allergic reaction), DIZZINESS (lightheadedness), DYSPNOEA (Breathing difficult), LYMPHADENOPATHY (Lymph nodes, enlarged ), LYMPHADENOPATHY (Swollen lymph nodes), LYMPHADENOPATHY (Painful lymphadenopathy) and PRURITUS (itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medication were provided. Patient had an allergic reaction: light-headedness,little trouble breathing, lymph nodes down in her  groin area in left side have grown, painful, itchy. Neck and throat lymph nodes were swollen as well. Patient was taking high blood pressure, diabetes,diabetic neuropathy, micro colitis medication as concomitant medication.
Initial and follow up information has been received from a nurse practitioner concerning a 44 year old white female patient with a concurrent condition of allergic to some antibiotics who on Jul 20 2004 (previously reported as Jul 03 2004) was vaccinated IM into the left deltoid with a first dose of pneumococcal 23v polysaccharide vaccine (lot 646494/1201N). Concomitant therapy included montelukast sodium and many other medications including acetaminophen (+) propoxyphene napsylate (Darvocet-N), albuterol (Proventil inhaler), cetirizine hydrochloride (Zyrtec) and lansopraxole (Prevacid). It was noted that on Jul 20 2004 the patient felt immediate pain, and a couple of hours later developed a red rash with warmth, burning and pain at the injection site, Today on Jul 22 2004 the patient had a splotchy rash, warmth and tenderness at the injection site. Unspecified medical attention was sought. The patient was told to follow up it there was no improvement. It was unknown if the patient recovered. There was no product quality complaint involved. Additional information has been requested.
pt recv 15JAN96 & 18APR97 pt devel a mild case of chickenpox;
I had severe abdominal pain and severe joint pain in many locations. The abdominal locations coincide with previous abdominal surgery. My right arm has radiating pain at elbow near ulnar nerve and radiating pain on thumb through middle fingers of right hand.  I lost muscle strength for all fingers on my right hand. I was told by doctors to use acetaminophen to manage the pain. This only made my bowel problems worse (see continuation below). I am no longer able to handwrite without difficulty and pain in the joint of middle finger.   I cannot type on computers anymore without extreme difficulty.  I had a high fever for 3 days after the first vaccine dose. I experienced no fever for the second dose.  I had severe anal pain along with severe diarrhea and watery stools. The anal pain was located inside my bowels where I had surgery for a fistula several years ago. It made it very uncomfortable to sit or apply pressure to my buttocks.  I had to lie on my side for several days until the pain diminished. I no longer have good bowel control nor sphincter muscle control. I no longer have regular stools and have smaller and softer or watery bowel movements 5 times day. I continue experience anal pain at least 3 times a week.  All these conditions except fever occurred after both doses of the vaccine. All these conditions continue to this day accompanied by moderate levels of pain. My doctors are dismissive of my problems and refuse and/or obstruct follow up care. Doctor told me to get the second vaccine dose even though I had a severe reaction to the first. I reluctantly followed this advice because of concern about the spread of COVID19 variants.  I suspect that Dr. has not submitted a VAERS on my behalf so I am submitting one myself.  Presently,  I can no longer conduct my life normally as I cannot know when my bowels will release uncontrolled. I have diminished motor function on my right hand. I have chronic pain in my abdomen which becomes acute at times.  I believe  I am suffering from a vascular disease related to the S protein as a study has revealed.
Large local reaction: approximately 2 hours following receipt of vaccine, noted small area of redness and warmth. The following day (4/24/04) the area had increased to his elbow and by 4/26/04, erythematous area was approximately 140 x 300 with accompanying warmth and tenderness; difficult to bend elbow.
Patient received dose of PFIZER Bivalent booster as her first dose of her primary series.
She also had pain in her arm; This is a spontaneous report from a contactable consumer or other non hcp. A female patient of an unspecified age received bnt162b2 (BNT162B2) solution for injection, dose 1 (Lot number expiry date was not reported) via an unspecified route of administration at arm on an unspecified date as a single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Prior to the vaccination the patient was not diagnosed with COVID-19. Since the vaccination the patient had not been tested for COVID-19. While calling to report adverse event for her wife and her wife's pain in arm after the Pfizer Covid 19 Vaccine the reporter mentioned that the vaccine was the same for her. She also had pain in her arm. Stated she had this with her first and second dose. With the second dose she states she also had fever and pain all over her body. Reporter stated she knew this was normal. Reporter stated that she is good and declines to complete a safety report for herself at this time. Reporter stated she has no questions regarding her own experience.   The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Noticed pain and Rash on back.  Went to Dr. at 6pm on 12/1/2010 and was diagnosed with Shingles. I am being treated with Valtrex twice a day for 5 days.
swollen rt LE, mostly foot 2 days p/vax;cont to remain swollen x 2wk;current plan is to observe & recheck approx 4wk;foot size was measured;counseled mom to return sooner for inc size, redness, tender;MD did not feel was vax related;
This spontaneous report was received from a registered nurse, referring to an unspecified number of patients of unknown genders and ages. No information regarding the patient's medical history, concurrent conditions or concomitant therapies was provided. On an unknown date, the patients were vaccinated with improperly stored dose of VARIVAX which had Lot number L030158 with an expiration date of 11-AUG-2017, lot # L048465 with an expiration date of 02-DEC-2017 and lot # M034583 with an expiration date of 27-JUL-2018 (strength, dose and route were not reported) for prophylaxis. It was confirmed that all the vaccines were reconstituted with sterile diluent (lot # and expiration date were not reported) which was stored in correct temperature range. No adverse effects were reported. It was reported that the vaccines were exposed to temperature of >-15 centigrade degrees (°C) but <-10 °C range, for a time frame of 1 hour. The temperature excursion was not recorded by a data logger and no previous excursions were reported for the vaccines. There was no product quality complaint involved. This is one of the several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1705USA001145: US-009507513-1705USA002376:
Mother developed red looking rash around the area with a little bump a week after receiving 1st dose; Injection site area was little hot; She also started with soreness on injection site on same day which progressed and getting worse; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Injection site area was little hot), VACCINATION SITE ERYTHEMA (Mother developed red looking rash around the area with a little bump a week after receiving 1st dose) and VACCINATION SITE PAIN (She also started with soreness on injection site on same day which progressed and getting worse) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     The patient's past medical history not included .    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.  On 03-Mar-2021, the patient experienced VACCINATION SITE PAIN (She also started with soreness on injection site on same day which progressed and getting worse). On 10-Mar-2021, the patient experienced VACCINATION SITE WARMTH (Injection site area was little hot). On an unknown date, the patient experienced VACCINATION SITE ERYTHEMA (Mother developed red looking rash around the area with a little bump a week after receiving 1st dose).  At the time of the report, VACCINATION SITE WARMTH (Injection site area was little hot), VACCINATION SITE ERYTHEMA (Mother developed red looking rash around the area with a little bump a week after receiving 1st dose) and VACCINATION SITE PAIN (She also started with soreness on injection site on same day which progressed and getting worse) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Pt was complaining of being light headed, dizzy, and nauseous 15 minutes after vaccine administration.  Pt was did not receive treatment and refused care.  Pt was assessed by paramedics and signed out AMA.
extreme menstrual cramps, vomiting, a bit of irregularity in cycle since June
Developed 99.0 temp, body aches, headache the day after ZOSTAVAX vaccine. Sx lasted 3 days after vaccine.
Redness and swelling in his left arm that got gradually worse and extended almost to the wrist. Patient's arm was also very sore. Patient did not take any medicine for this before seeing the provider. Per patient's wife the doctor diagnosed it as "violent reaction and cellulitis" Cephalexin 500 mg capsule 1 BID x 7 days. Started on 10/26/17 and still continuing.
Area of injection (given 4/7/08) just started to redden and itch yesterday 4/1508. Area of redness is 2" x 2 1/2". Site marked by Dr.. Antibiotic Dicloxicillin and Atarax x 1 week. Pt will phone if no improvement.
Date and time of vaccination: (list both if they received both shots): 1-7-2021 approx. @ 11:30am: 2-4-2021 approx. @ 11:30am: Brand and lot of vaccine: Moderna LOT #  211L20A: Moderna LOT # unable to read per client.
Accidental exposure. FLUMIST was given to this patient who is 28 weeks pregnant by accident.
Pt was administered 1st series of Gardasil vaccine at 10:49 AM. After sitting in the waiting area for about 5 minutes pt c/o nausea, ringing in ears, feeling "shakey". Pt was escorted to exam table and instructed to rest until she felt better. Vital signs were taken and were stable. Pt was evaluated by Dr. and released after about 10 minutes without limitations.
went outside and planted and it took her 15 minutes when it should of taken her 5 minutes; severe lethargy; Severe Backache; head ache; Sleeps a lot; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 46 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 10May2021 09:00 (Lot number: EW0169) at the age of 46 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: LETHARGY (non-serious) with onset 10May2021, outcome "not recovered", described as "severe lethargy"; BACK PAIN (non-serious) with onset 10May2021, outcome "not recovered", described as "Severe Backache"; HEADACHE (non-serious) with onset 10May2021, outcome "not recovered", described as "head ache"; SOMNOLENCE (non-serious) with onset 10May2021, outcome "not recovered", described as "Sleeps a lot"; MOBILITY DECREASED (non-serious), outcome "unknown", described as "went outside and planted and it took her 15 minutes when it should of taken her 5 minutes". Therapeutic measures were taken as a result of lethargy, back pain, headache.  Additional information: Treatment: Bed and Tylenol, Rexall Sports Rubbing Alcohol Cream, Muscle Freeze like Icy Hot, Acetaminophen. AEs did not require a visit to Emergency Room or Physician Office. Prior Vaccinations (within 4 weeks), AE(s) following prior vaccinations, Family Medical History Relevant to AE(s), Relevant Tests: None.  No follow-up attempts are possible. No further information is expected.
The day after the vaccine I experienced the normal flu symptoms that they spoke about but in addition I started having heart palpitations (skipped beats) that have progressively gotten worse over these two weeks. In addition my previously diagnosed Fibromyalgia has flared back with nerve pain, digestive issues, fatigue, joint and muscle pain, palpitations, etc.
9/1/06 started with respiratory symptoms of mainly nasal congestion with in 2-3 hours after vaccination then over progressed 24 hrs following day on 9/2/06 developed facial swelling, flushing, chest tightness, thick tongue and presented to Emergency.
Patient was admitted for hospitalization with an acute kidney injury and hyperkalemia attributed to a new medication (dapagliflozin). Patient tested positive for COVID during routine hospital admission testing. Patient is presumed to be asymptomatic. Of note, the patient did receive their COVID booster that same day (11/12/2021, Moderna, Lot 051F21A. No adverse reaction noted with the booster.
Extreme fatigue, vertigo, fever of 103, chills, shaking, headache, achiness
terrible headache; dreaming or recalling a dream while standing up awake; feelng faint out of the blue; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55 year-old male patient received bnt162b2 (BNT162B2), administration date 01Dec2021 (Lot number: 4) at the age of 55 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEADACHE (non-serious) with onset 01Dec2021, outcome "recovered with sequelae", described as "terrible headache"; DAYDREAMING (non-serious) with onset 01Dec2021, outcome "recovered with sequelae", described as "dreaming or recalling a dream while standing up awake"; DIZZINESS (non-serious) with onset 01Dec2021, outcome "recovered with sequelae", described as "feelng faint out of the blue". Relevant laboratory tests and procedures are available in the appropriate section. No follow-up attempts are possible. No further information is expected.  Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, has the patient been tested for COVID-19.
redness over lt leg seen @ office 30AUg93 area is about 6cm in diameter, not tender to the touch & no incr warmth as reported by PMD;
Vomiting (dry heaving) lasting over 10 hours Severe Headache  Fever
6 minutes after receiving vaccine, pt felt dizzy and felt "off".  Chest started feeling heavy, and felt like throat was closing.  Pt received benadryl IV in ER.
Fever of 101; body aches; This is a spontaneous report from a non-contactable consumer (patient's spouse). A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (lot number and expiry date: unknown) as dose 1, single, for Covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient received his first shot and developed fever of 101 and body aches on unspecified date. Outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
No signs or symptoms reported.; Medical assistant called to report a temperature excursion that occurred on 3/AUG/2021 and 5/AUG/2021. See case number 02007815 for TE details. ROTATEQ was administered to four patients; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. No information was provided regarding the patient's pertinent medical history, concomitant medications, past drug reactions or allergies.  On an unspecified date in 2021, the patient was vaccinated with a one (1) time dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) orally (exact dose was not reported; lot number 1707449, was verified to be a valid lot number with an expiration date reported and established as 28-MAR-2021) for prophylaxis after that the vaccine experienced a temperature excursion of 35.4 degrees Fahrenheit (F) and 35.8 degrees Fahrenheit (F) during a time frame of 15 minutes (cumulative) that occurred on 03-AUG-2021 and 05-AUG-2021 (product storage error). It was stated that no previous temperature excursion was reported.  It was reported that the patient did not experienced any signs or symptoms after the administration. No additional adverse event (AE) was reported.  This is one of four reports received from the same reporter.; Sender's Comments:  US-009507513-2109USA002597:
Patient's left wrist ganglion cyst grew in size. Both the patient and his mother are convinced that he woke up the morning after the 2nd HPV shot with a notable increase in the size of his ganglion cyst. They also stated that they are convinced that the ganglion cyst originated after having received the first dose of HPV vaccine on 6/27/17, but they did not bring him to see me for his ganglion cyst until 12/12/17. The ganglion cyst has always been asymptomatic: no pain, no limit in his range of motion. He saw an orthopedic hand specialist for it on 12/14/17, who recommended monitoring it clinically. He again saw me for it on 1/23/18, after it had increased in size, and it is now approximately 1 cm in size but still painless, nontender, and without any limit of his ROM, so I recommended continuing to monitor it and to return if it causes pain or limited range of motion or continues to grow. I also told them I would file this VAERS report but felt that it was not related to the HPV vaccine.
Employee had Fluzone vaccine on 10/01/2019 in Employee Health office. Employee states she began to have "vague symptoms" involving bilateral feet and lower legs on 10/17/2019. On 10/21/2019 sypmtons became worse. On 10/22/2019 employee reported sypmtoms to her direct supervisor and was referred to Employee Health. Sypmtons included numb, cold, wet sensation in both feet, muscle fatigue and difficulty walking. Employee was referred to her PCP for evaluation. PCP referred employee to Neurology for evaluation on 10/23/2019. Per employee, at neurologist follow-up on 11/05/2019, neurologist stated "probable adverse reaction to flu vaccine".
Tested positive for COVID-19 virus; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive for COVID-19 virus) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No recorded medical history.).    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, the patient experienced COVID-19 (Tested positive for COVID-19 virus). At the time of the report, COVID-19 (Tested positive for COVID-19 virus) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 24-Mar-2021, SARS-CoV-2 test: positive (Positive) Tested positive for COVID-19 virus.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
This spontaneous report was received from a nurse practitioner and refers to a 25-year-old male patient  with history of seizure. The patient's concurrent conditions included tobacco abuse and cannabis abuse. The patient had no concomitant therapies and no drug reactions or allergies. On 12-SEP-2017, the patient was vaccinated with "1 dose" of GARDASIL 9 lot number N007931 with expiration date 17-NOV-2019 (dose number, route and anatomical location were not reported) for human papillomavirus (HPV) prevention. On the same date about 15 minutes after vaccination with GARDASIL 9 while the patient was still in the office, he had a Grand-Mal seizure (generalised tonic-clonic seizure). The nurse practitioner called the emergency medical service (EMS) and the patient was took to the hospital as treatment for the event. At the time of the report, the outcome of the generalised tonic-clonic seizure was unknown. The relatedness between the event and therapy with GARDASIL 9 was not reported. The reporter considered the generalised tonic-clonic seizure to be serious as possible life threatening event. Upon internal review, generalised tonic-clonic seizure was determined to be medically significant event.
30APR92 felt warm & fussy 30APR92 evening, muscle soreness @ site; 4MAY92 & 5MAY92 t103.1 w/APAP; 6MAY92 lump w/tenderness behind lt ear; 7MAY92 rash, fine, pink, rough, lasted 5 days; started on face then covered trunk, no fever w/rash;
Case number PHEH2014US024352, is an initial spontaneous report from a nurse received on 02 Dec 2014 with a follow up information received from the nurse on 19 Jan 2015. This report refers to a 76-year-old male patient. Historical conditions were not reported. No concomitant medication was reported. His vaccination history included administration of previous FLUVIRIN (batch number: not reported) which was previously tolerated. The patient was vaccinated with FLUVIRIN (batch number: 14511P, expiry date: Mar 2015) intramuscularly in the right deltoid at a dose of 0.5 ml on 03 Nov 2014. The nurse reported that before vaccination the prefilled syringe (PFS) of FLUVIRIN was stored at 49 degree F for 1 hour and 15 minutes. The reporter confirmed that the patient did not experience any adverse reaction following administration of incorrectly stored vaccine. Follow up information received from the nurse on 19 Jan 2015: Updated vaccination history, site of vaccination and reporter's comment.
Received vaccine 8-9-07 area become red, sore, warm to touch, slightly swollen 2" around site and 3" below site - on 8/11 and 8/12/07 - took Benadryl, ice to area, resolved by 8/13/07" info per patient.
within a minute of patient leaving the consulation room after receiving the vaccine - patient sat down and passed out. When I looked over, I saw patient experiences minor convulsions. She was still in her chair. Episode lasted not even 10 seconds. Patient awoke and said she blacked out. She was coherent and responsive. We called 911. Patient said she has no history of seizures or low blood sugar. She said she tends to faint when giving blood or during vaccines due to the needle. Paramedic checked patient out and cleared the patient. No ambulance was taken. Will call patient tomorrow to follow up.